SABCS 2022 | The latest news on the management of breast cancer patients with brain metastases

Gaia Griguolo, MD, Istituto Oncologico Veneto, Padua, Italy, talks on the latest news on the management of breast cancer patients with brain metastases, including the utility of HER2-targeted treatments that have demonstrated activity in the central nervous system (CNS). The Phase III HER2CLIMB-05 (NCT02614794) trial was the first completed Phase III randomized trial to include patients with brain metastasis, which demonstrated tucatinib added to trastuzumab/capecitabine to significantly reduce risk of death and disease progression in patients with heavily pre-treated metastatic HER2-positive breast cancer, including those with untreated or previously treated brain metastasis. The Phase II TUXEDO-1 (NCT04752059) trial investigating trastuzumab deruxtecan in HER2-positive breast cancer with brain metastasis, which yielded high intracranial response rates. The Phase II DEBBRAH (NCT04420598) trial is exploring trastuzumab deruxtecan in patients with HER2-positive and HER2-low breast cancer with untreated brain metastasis, the results of which are to be presented at the San Antonio Breast Cancer Symposium (SABCS) 2022. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.